Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)

NCT06643117 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
25
Enrollment
INDUSTRY
Sponsor class

Stopped Formycon concluded that continuing the trial is no longer necessary for the development and approval of FYB206. The therapeutic comparability of FYB206 to Keytruda can be demonstrated based on comprehensive analytical and PK comparability data

Conditions

Interventions

Sponsor

Formycon AG